# Shervin Ghaemmaghami

> Shervin Ghaemmaghami is a Series B investor at F-Prime (Boston) backing Software and Life Science. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [F-Prime](https://shizune.co/investors/profile/f-prime-capital-partners)
- Location: Boston, United States
- Total investments: 7
- Last investment: May 2023
- Lead investor: 29%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/mrshervin/
- X (Twitter): https://twitter.com/mrshervin
- Website: https://x.com/mrshervin

Shervin Ghaemmaghami is a Series B investor at F-Prime in Boston focused on Software and Life Science. Shervin Ghaemmaghami is based out of Cambridge, Massachusetts and is the Operating Partner of F-Prime. Shervin previously worked at The Atlantic as a Group Managing Director. Shervin Ghaemmaghami attended the Massachusetts Institute of Technology.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Software | 3 | 43% |
| Life Science | 2 | 29% |
| Biotechnology | 2 | 29% |
| SaaS | 1 | 14% |
| Billing | 1 | 14% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 43% |
| Seed | 1 | 14% |
| Series C | 1 | 14% |
| Series D | 1 | 14% |
| Convertible Note | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 43% |
| Canada | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| BenchSci | BenchSci uses AI to empower scientists to run more successful experiments to accelerate drug discovery.The company empowers scientists with advanced biomedical artificial intelligence to run more successful experiments. Backed by F-Prime, Gradient Ventures (Google’s AI fund), and Inovia Capital, BenchSci's proprietary technology acceleratesscience pharmaceutical companies and over 4,300 research centers worldwide. | $69.6M | Series D | May 25, 2023 |  |
| BenchSci | BenchSci uses AI to empower scientists to run more successful experiments to accelerate drug discovery.The company empowers scientists with advanced biomedical artificial intelligence to run more successful experiments. Backed by F-Prime, Gradient Ventures (Google’s AI fund), and Inovia Capital, BenchSci's proprietary technology acceleratesscience pharmaceutical companies and over 4,300 research centers worldwide. | $22M | Series B | Feb 04, 2020 |  |
| Recurly | Recurly gracefully handles all the complexities of subscription billing and revenue optimization.Recurly, Inc. provides enterprise-class recurring billing management for thousands of subscription-based SaaS, Web 2.0, Mobile, content and publishing businesses worldwide. Since it’s launch in January of 2010, Recurly has deployed subscriptionbilling for companies throughout North America and the European Union. As the leading recurring billing platform Recurly ensures setup is easy, integrations are quick and their service sales with the needs of any business. With Recurly merchants can be ready to accept payments and focus on growing sales in days not weeks.They improve subscriber economicsRecurly reduces subscriber churn resulting from unnecessary credit card declines. Card recycling delivers a 10-27% improvement in recovered invoices.They improve operational efficiencyTheir dashboard helps merchant staff easily handle customer-related billing issues. Upgrades, downgrades, voids and refunds are all handled with a few simple clicks. No training required.They reduce PCI compliance costsAs a level 1 PCI compliant service provider Recurly greatly reduces your costs and obligations associated with PCI compliance. | $19.5M | Series C | Sep 27, 2019 |  |
| Benchling | Benchling is the modern software platform purpose-built for life science R&D. Hundreds of thousands of scientists using cutting-edge techniques like CRISPR, CAR-T immunotherapy, and genetic engineering depend on our suite of cloud applications to design DNA, collaborate on experiments, manage research workflows, and make critical R&Ddecisions. Benchling is powering breakthrough research on biotherapeutics, biofuels, and biomaterials at leading life science companies and the world's most renowned academic labs.The company is focusing on life science collaboration, both private and public, through creating cloud-based software tools for digital DNA sequence editing, designing and running experiments, analyzing data, and sharing research. Benchling software includes an electronic lab notebook that allows researchers to document their experiments.It was founded in 2012 and is headquartered in San Francisco, California, United States. | $14.5M | Series B | Jun 14, 2018 |  |
| ReadMe | ReadMe provides every company the ability to easily create beautiful documentation and build loyal, productive developer communities.With ReadMe, build developer portals that combine support, tutorials, topical guides, and API exploration. ReadMe makes it trivial to keep docs up-to-date and has community oriented features that help driveadoption. | $1M | Seed | Jun 19, 2015 |  |
| Recurly | Recurly gracefully handles all the complexities of subscription billing and revenue optimization.Recurly, Inc. provides enterprise-class recurring billing management for thousands of subscription-based SaaS, Web 2.0, Mobile, content and publishing businesses worldwide. Since it’s launch in January of 2010, Recurly has deployed subscriptionbilling for companies throughout North America and the European Union. As the leading recurring billing platform Recurly ensures setup is easy, integrations are quick and their service sales with the needs of any business. With Recurly merchants can be ready to accept payments and focus on growing sales in days not weeks.They improve subscriber economicsRecurly reduces subscriber churn resulting from unnecessary credit card declines. Card recycling delivers a 10-27% improvement in recovered invoices.They improve operational efficiencyTheir dashboard helps merchant staff easily handle customer-related billing issues. Upgrades, downgrades, voids and refunds are all handled with a few simple clicks. No training required.They reduce PCI compliance costsAs a level 1 PCI compliant service provider Recurly greatly reduces your costs and obligations associated with PCI compliance. | $12M | Series B | Oct 20, 2014 |  |
| ReadMe | ReadMe provides every company the ability to easily create beautiful documentation and build loyal, productive developer communities.With ReadMe, build developer portals that combine support, tutorials, topical guides, and API exploration. ReadMe makes it trivial to keep docs up-to-date and has community oriented features that help driveadoption. |  | Convertible Note |  |  |

7 of 7 investments shown.

## Co-investors
- [Inovia Capital](https://shizune.co/investors/profile/inovia-capital) — VC Fund, 3 deals together
- [Golden Ventures](https://shizune.co/investors/profile/golden-venture-partners) — VC Fund, 2 deals together
- [Greycroft](https://shizune.co/investors/profile/greycroft) — VC Fund, 2 deals together
- [Polaris Partners](https://shizune.co/investors/profile/polaris-partners) — VC Fund, 2 deals together
- [BDC Venture Capital](https://shizune.co/investors/profile/bdc-venture-capital) — VC Fund, 1 deal together
- [Benchmark](https://shizune.co/investors/profile/benchmark) — VC Fund, 1 deal together

## About F-Prime

VC Fund · Cambridge, United States

F-Prime enables companies to turn their boldest ambitions into world-changing breakthroughs in life sciences, technology, healthtech + services, and crypto. Our legacy spans over 50 years, built on the belief that the best investors share the same entrepreneurial spirit of the founders they back—and that conviction still guides us today.Inhealthcare, we focus on therapeutics, medtech, and healthtech + services in a stage-agnostic fashion. In technology, we focus on enterprise software, fintech and frontier tech, and crypto. While we’re early-stage investors by choice, we’ll back exceptional teams at any stage.Today, our $4.8 billion under management support breakthroughs across healthcare and technology. Our seasoned team of scientists, engineers, physicians, operators, and investors bring real world expertise to help companies accelerate their path to scalable growth, always with an eye towards a shared vision—achieving something incredible.

5 contacts available at F-Prime.

| Name | Title | Profile |
| --- | --- | --- |
| Alexander Pasteur | Partner | https://shizune.co/investors/profile/alex-pasteur |
| Sanjay Aggarwal | Venture Partner | https://shizune.co/investors/profile/sanjay-aggarwal-3 |
| Shervin Ghaemmaghami | Operating Partner | https://shizune.co/investors/profile/shervin-ghaemmaghami |
| Stacie Weninger | Executive Director | https://shizune.co/investors/profile/stacie-weninger |
| Ben Gorman | Principal | https://shizune.co/investors/profile/ben-gorman |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Shervin Ghaemmaghami invest in?

Shervin Ghaemmaghami invests primarily in Software, Life Science and Biotechnology startups, most often at Series B and Seed stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Shervin Ghaemmaghami last invest?

The most recent investment recorded for Shervin Ghaemmaghami closed in May 2023. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co